Tracked shipping is included
Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
The relaxation response was significantly reduced in preparations and endothelium-denuded preparations, and was further inhibited by NOS inhibitors
Stenzel, W., Soltek, S., Schluter, D
Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD